Corpus overview


MeSH Disease

Human Phenotype

Fever (9)

Anosmia (6)

Cough (4)

Pneumonia (3)

Myalgia (3)


    displaying 121 - 130 records in total 181
    records per page

    Covid-19 Seroprevalence SERO rate in healthy blood SERO donors from a community under strict lockdown measures

    Authors: Maher A Sughayer; Asem Mansour; Abeer Al Nuirat; Lina Souan; Mohammad Ghanem; Mahmoud Siag

    doi:10.1101/2020.06.06.20123919 Date: 2020-06-07 Source: medRxiv

    Background: Covid-19 seroprevalence SERO rates and serological tests SERO are important tools in understanding the epidemiology of the disease and help in the fight against it. Seroprevalence SERO rates vary according to the population studied and the test employed and they range from 0.133 to 25.7%. The purpose of this study is to assess the seroprevalence SERO rate in a population of healthy blood SERO donors living under strict lockdown measures in Jordan which has in total 71 confirmed cases TRANS per million population. Methods: Left over sera and plasma SERO samples from 746 healthy blood SERO donors were tested using a commercially available FDA approved kit having a specificity of 100%. External positive controls were used for validation. Results: More than 80% of the donors were men 18-63 year old and residing in the capital city of Jordan, Amman. All tested specimens were negative yielding a zero seroprevalence SERO rate in this healthy blood SERO donor population. Conclusion: Strict lockdown measures effectively limit intracommunity spread of the infection MESHD, however at the cost of lack of any acquired community immunity. Additionally the use of highly specific test is recommended in low prevalence SERO setting.

    Side by side comparison of three fully automated SARS-CoV-2 antibody SERO assays with a focus on specificity

    Authors: Thomas Perkmann; Nicole Perkmann-Nagele; Marie-Kathrin Breyer; Robab Breyer-Kohansal; Otto C Burghuber; Sylvia Hartl; Daniel Aletaha; Daniela Sieghart; Peter Quehenberger; Rodrig Marculescu; Patrick Mucher; Robert Strassl; Oswald F Wagner; Christoph J Binder; Helmuth Haslacher

    doi:10.1101/2020.06.04.20117911 Date: 2020-06-05 Source: medRxiv

    Background: In the context of the COVID-19 pandemic, numerous new serological test SERO systems for the detection of anti- SARS-CoV-2 antibodies SERO have become available quickly. However, the clinical performance SERO of many of them is still insufficiently described. Therefore we compared three commercial, CE-marked, SARS-CoV-2 antibody SERO assays side by side. Methods: We included a total of 1,154 specimens from pre-COVID-19 times and 65 samples from COVID-19 patients ([≥]14 days after symptom onset TRANS) to evaluate the test performance SERO of SARS-CoV-2 serological assays SERO by Abbott, Roche, and DiaSorin. Results: All three assays presented with high specificities: 99.2% (98.6-99.7) for Abbott, 99.7% (99.2-100.0) for Roche, and 98.3% (97.3-98.9) for DiaSorin. In contrast to the manufacturers' specifications, sensitivities SERO only ranged from 83.1% to 89.2%. Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar's test revealed significant differences between results obtained from Roche and DiaSorin. However, at low seroprevalences SERO, the minor differences in specificity resulted in profound discrepancies of positive predictability at 1% seroprevalence SERO: 52.3% (36.2-67.9), 77.6% (52.8-91.5), and 32.6% (23.6-43.1) for Abbott, Roche, and DiaSorin, respectively. Conclusion: We find diagnostically relevant differences in specificities for the anti- SARS-CoV-2 antibody SERO assays by Abbott, Roche, and DiaSorin that have a significant impact on the positive predictability of these tests.

    Are antibodies tests SERO accurate? Understanding predictive values and uncertainty of serology tests for the novel coronavirus.

    Authors: Naomi C Brownstein; Yian A Chen

    doi:10.1101/2020.06.04.20122358 Date: 2020-06-05 Source: medRxiv

    Antibodies testing SERO in the coronavirus era is frequently promoted, but the underlying statistics behind their validation has come under more scrutiny in recent weeks. We provide calculations, interpretations, and plots of positive and negative predictive values SERO under a variety of scenarios. Prevalence SERO, sensitivity SERO, and specificity are estimated within ranges of values from researchers and antibodies SERO manufacturers. Illustrative examples are highlighted, and interactive plots are provided in the Supplementary Material. Implications are discussed for society overall and across diverse locations with different levels of disease burden. Specifically, the proportion of positive serology tests that are false can differ drastically from up to 3% to 88% for people from different places with different proportions of infected people MESHD in the populations while the false negative rate is typically under 10%.

    Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

    Authors: Suzanne Pickering; Gilberto Betancor; Rui Pedro Galao; Blair Merrick; Adrian W Signell; Harry D Wilson; Mark Tan Kia Ik; Jeffrey Seow; Carl Graham; Sam Acors; Neophytos Kouphou; Kathryn JA Steel; Oliver Hemmings; Amita Patel; Gaia Nebbia; Sam Douthwaite; Lorcan O'Connell; Jakub Luptak; Laura McCoy; Philip JM Brouwer; Marit J van Gils; Rogier W Sanders; Rocio Martinez Nunez; Karen Bisnauthsing; Geraldine O'Hara; Eithne MacMahon; Rahul Batra; Michael H Malim; Stuart JD Neil; Katie Doores; Jonathan D Edgeworth

    doi:10.1101/2020.06.02.20120345 Date: 2020-06-04 Source: medRxiv

    There is a clear requirement for an accurate SARS-CoV-2 antibody SERO test, both as a complement to existing diagnostic capabilities and for determining community seroprevalence SERO. We therefore evaluated the performance SERO of a variety of antibody testing SERO technologies and their potential as diagnostic tools. A highly specific in-house ELISA SERO was developed for the detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies SERO and used for the cross-comparison of ten commercial serological assays SERO - a chemiluminescence-based platform, two ELISAs SERO and seven colloidal gold lateral flow immunoassays SERO (LFIAs) - on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-pandemic negatives. There was a wide variation in the performance SERO of the different platforms, with specificity ranging from 82% to 100%, and overall sensitivity SERO from 60.9% to 87.3%. However, the head to head comparison of multiple serodiagnostic assays on identical sample sets revealed that performance SERO is highly dependent on the time of sampling, with sensitivities SERO of over 95% seen in several tests when assessing samples from more than 20 days post onset of symptoms TRANS. Furthermore, these analyses identified clear outlying samples that were negative in all tests, but were later shown to be from individuals with mildest disease presentation. Rigorous comparison of antibody testing SERO platforms will inform the deployment of point of care technologies in healthcare settings and their use in the monitoring of SARS-CoV-2 infections MESHD.

    Regional Difference in Seroprevalence SERO of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing SERO

    Authors: Morihito Takita; Tomoko Matsumura; Kana Yamamoto; Erika Yamashita; Kazutaka Hosoda; Tamae Hamaki; Eiji Kusumi

    doi:10.1101/2020.06.03.20121020 Date: 2020-06-04 Source: medRxiv

    The serosurvey is an alternative way to know the magnitude of the population infected by coronavirus disease MESHD 2019 (COVID-19) since the expansion of capacity of the polymerase chain reaction (PCR) to detect the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) was delayed. We herein report seroprevalence SERO of COVID-19 accessed in the two community clinics in Tokyo. The point-of-care immunodiagnostic test was implemented to detect the SARS-CoV-2 specific IgG antibody SERO in the peripheral capillary blood SERO. The overall positive percentage of SARS-CoV-2 IgG antibody SERO is 3.83% (95% confidence interval: 2.76-5.16) for the entire cohort (n =1,071). The central Tokyo of 23 special wards exhibited a significantly higher prevalence SERO compared to the other area of Tokyo (p =0.02, 4.68% [95%CI: 3.08-6.79] versus 1.83 [0.68-3.95] in central and suburban Tokyo, respectively). The seroprevalence SERO of the cohort surveyed in this study is low for herd immunity, which suggests the need for robust disease control and prevention. A community-based approach, rather than state or prefectural levels, is of importance to figure out profiles of the SARS-COV-2 outbreak.

    Evaluation of serological tests SERO for SARS-CoV-2: Implications for serology testing in a low- prevalence SERO setting

    Authors: Katherine Bond; Suellen Nicholson; Seok Lim; Theo Karapanagiotidis; Eloise Williams; Douglas Johnston; Tuyet Hoang; Cheryll Sia; Damian Purcell; Sharon Lewin; Mike Catton; Benjamon P Howden; Deborah Williamson

    doi:10.1101/2020.05.31.20118273 Date: 2020-06-03 Source: medRxiv

    Background: Robust serological assays SERO are essential for long-term control of the COVID-19 pandemic. Many recently released point-of-care (PoCT) serological assays SERO have been distributed with little pre-market validation. Methods: Performance SERO characteristics for five PoCT lateral flow devices approved for use in Australia were compared to a commercial enzyme immunoassay SERO ( ELISA SERO) and a recently described novel surrogate virus neutralisation test (sVNT). Results: Sensitivities SERO for PoCT ranged from 51.8% (95% CI 43.1 to 60.4%) to 67.9% (95% CI 59.4-75.6%), and specificities from 95.6% (95% CI 89.2-98.8%) to 100.0% (95% CI 96.1-100.0%). Overall ELISA SERO sensitivity SERO for either IgA or IgG detection was 67.9% (95% CI 59.4-75.6), increasing to 93.8% (95% CI 85.0-98.3%) for samples >14 days post symptom onset TRANS. Overall, sVNT sensitivity SERO was 60.9% (95% CI 53.2-68.4%), rising to 91.2%% (95% CI 81.8-96.7%) for samples collected >14 days post- symptom onset TRANS, with a specificity 94.4% (95% CI 89.2-97.5%), Conclusion: Performance SERO characteristics for COVID-19 serological assays SERO were generally lower than those reported by manufacturers. Timing of specimen collection relative to onset of illness or infection MESHD is crucial in the reporting of performance SERO characteristics for COVID-19 serological assays SERO. The optimal algorithm for implementing serological testing SERO for COVID-19 remains to be determined, particularly in low- prevalence SERO settings.

    High seroprevalence SERO for SARS-CoV-2 among household members of essential workers detected using a dried blood SERO spot assay

    Authors: Thomas W McDade; Elizabeth McNally; Aaron Zelikovich; Richard D'Aquila; Brian Mustanski; Aaron Miller; Lauren Vaught; Nina Reiser; Elena Bogdanovic; Katherine Fallon; Alexis Demonbreun

    doi:10.1101/2020.06.01.20119602 Date: 2020-06-02 Source: medRxiv

    Objective: Serological testing SERO is needed to investigate the extent of transmission TRANS of SARS-CoV-2 from front-line essential workers to their household members. However, the requirement for serum SERO/ plasma SERO limits serological testing SERO to clinical settings where it is feasible to collect and process venous blood SERO. To address this problem we developed a serological test SERO for SARS-CoV-2 IgG antibodies SERO that requires only a single drop of finger stick capillary whole blood SERO, collected in the home and dried on filter paper (dried blood SERO spot, DBS). Methods: An ELISA SERO to the receptor binding domain of the SARS-CoV-2 spike protein was optimized to quantify IgG antibodies SERO in DBS. Samples were self-collected from a community sample of 232 participants enriched with health care workers, including 30 known COVID-19 cases and their household members. Results: Among 30 individuals sharing a household with a virus- confirmed case TRANS of COVID-19, 80% were seropositive. Of 202 community individuals without prior confirmed acute COVID-19 diagnoses, 36% were seropositive. Of documented convalescent COVID-19 cases from the community, 29 of 30 (97%) were seropositive for IgG antibodies SERO to the receptor binding domain. Conclusion: DBS ELISA SERO provides a minimally-invasive alternative to venous blood SERO collection. Early analysis suggests a high rate of transmission among household TRANS members. High rates of seroconversion were also noted following recovery from infection. Serological testing SERO for SARS-CoV-2 IgG antibodies SERO in DBS samples can facilitate seroprevalence SERO assessment in community settings to address epidemiological questions, monitor duration of antibody SERO responses, and assess if antibodies SERO against the spike protein correlate with protection from reinfection.

    Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay SERO

    Authors: Marc Emmenegger; Elena De Cecco; David Lamparter; Raphael P. B. Jacquat; Daniel Ebner; Matthias M Schneider; Itzel Condado Morales; Dezirae Schneider; Berre Dogancay; Jingjing Guo; Anne Wiedmer; Julie Domange; Marigona Imeri; Rita Moos; Chryssa Zografou; Chiara Trevisan; Andres Gonzalez-Guerra; Alessandra Carrella; Irina L. Dubach; Catherine K. Xu; Georg Meisl; Vasilis Kosmoliaptsis; Tomas Malinauskas; Nicola Burgess-Brown; Ray Owens; Juthathip Mongkolsapaya; Stephanie Hatch; Gavin R. Screaton; Katharina Schubert; John D. Huck; Feimei Liu; Florence Pojer; Kelvin Lau; David Hacker; Elsbeth Probst-Mueller; Carlo Cervia; Jakob Nilsson; Onur Boyman; Lanja Saleh; Katharina Spanaus; Arnold von Eckardstein; Dominik J. Schaer; Nenad Ban; Ching-Ju Tsai; Jacopo Marino; Gebhard F. X. Schertler; Nadine Ebert; Volker Thiel; Jochen Gottschalk; Beat M. Frey; Regina Reimann; Simone Hornemann; Aaron M. Ring; Tuomas P. J. Knowles; Ioannis Xenarios; David I. Stuart; Adriano Aguzzi

    doi:10.1101/2020.05.31.20118554 Date: 2020-06-02 Source: medRxiv

    We describe the evolution of severe acute respiratory coronavirus MESHD 2 (SARS-CoV-2) seroprevalence SERO in the greater area of Zurich, Switzerland, a region that has been only mildly hit by the pandemic in spite of hosting an international airport hub and a highly mobile population. Seroprevalence SERO studies in low- prevalence SERO settings require large sample sizes and high-specificity methodologies. To address this particular challenge, we developed a Tripartite Automated Blood SERO Immunoassay SERO to assess the IgG response against three SARS-CoV-2 proteins on approximately 40'000 samples from university hospital patients and healthy blood SERO donors. The seroprevalence SERO increased in March 2020 (0.3%; CI95%: 0.1% - 0.5%) in the cohort of the hospital patients but rapidly plateaued in April at 1.1-1.3%, with a slight drop in June, then decreased in July to 0.3-0.7%. Seropositive samples were confirmed with Western Blotting and liquid-phase binding assays. Employing a dynamic transmission TRANS model that describes SARS-CoV-2 transmission TRANS and seroconversion in the general population of the Canton of Zurich, we estimated an infection fatality ratio of 0.6% (CI95%: 0.4%-0.8%). We conclude that a small proportion of the population in the greater area of Zurich has been exposed to SARS-CoV-2, with an IFR that is similar to that of other European areas. The evolution of seroprevalence SERO points to a high effectiveness of containment measures and/or to rapid loss of humoral responses.

    Immunochromatographic assays for COVID-19 epidemiological screening: our experience

    Authors: Andrea Bartolini; Margherita Scapaticci; Marina Bioli; Tiziana Lazzarotto; Maria Carla Re; Rita Mancini

    doi:10.1101/2020.05.28.20116046 Date: 2020-06-02 Source: medRxiv

    In March 2020, the World Health Organization (WHO) declared a pandemic caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Due to the absence of effective treatment or biomedical prevention, understanding potential post infection immunity has important implications for epidemiologic assessments. For this reason, increasing number of in vitro diagnostic companies are developing serological assays SERO to detect antibodies SERO against SARS-CoV-2, but most of them lack the validation by third parties in relation to their quality, limiting their usefulness. We submitted to serological screening SERO by two different immunochromatographic (IC) rapid testing SERO for detection of IgG and IgM against SARS-CoV-2, 151 asymptomatic TRANS or minimally symptomatic healthcare workers previously tested positive for SARS-CoV-2 RT-PCR in order to evaluate the performance SERO of rapid assays. Results showed discrepancies between molecular and IC results, and an inconsistency of immunoglobulins positivity patterns when compared to ELISA SERO/CLIA results, highlighting the absolute necessity of assays performance SERO validation before their marketing and use, in order to avoid errors in the results evaluation at both clinical and epidemiological level.

    Remarkable variability in SARS-CoV-2 antibodies SERO across Brazilian regions: nationwide serological household survey in 27 states

    Authors: Pedro Hallal; Fernando Hartwig; Bernardo Horta; Gabriel D Victora; Mariangela Silveira; Claudio Struchiner; Luis Paulo Vidaletti; Nelson Neumann; Lucia C Pellanda; Odir A Dellagostin; Marcelo N Burattini; Ana M Menezes; Fernando C Barros; Aluisio J Barros; Cesar G Victora

    doi:10.1101/2020.05.30.20117531 Date: 2020-05-30 Source: medRxiv

    Population based data on COVID-19 are essential for guiding policy. We report on the first wave of seroprevalence SERO surveys relying upon on household probabilistic samples of 133 large sentinel cities in Brazil, including 25,025 participants from all 26 states and the Federal District. Seroprevalence SERO of antibodies to SARS-CoV-2 SERO, assessed using a lateral flow rapid test SERO, varied markedly across the cities and regions, from below 1% in most cities in the South and Center-West regions to up to 25% in the city of Breves in the Amazon (North) region. Eleven of the 15 cities with the highest seroprevalence SERO were located in the North, including the six cities with highest prevalence SERO which were located along a 2,000 km stretch of the Amazon river. Overall seroprevalence SERO for the 90 cities with sample size of 200 or greater was 1.4% (95% CI 1.3-1.6). Extrapolating this figure to the population of these cities, which represent 25% of the country population, led to an estimate of 760,000 cases, as compared to the 104,782 cases reported in official statistics. Seroprevalence SERO did not vary significantly between infancy and age TRANS 79 years, but fell HP by approximately two-thirds after age TRANS 80 years. Prevalence SERO was highest among indigenous people (3.7%) and lowest among whites (0.6%), a difference which was maintained when analyses were restricted to the North region, where most indigenous people live. Our results suggest that pandemic is highly heterogenous, with rapid escalation in the North and Northeast, and slow progression in the South and Center-West regions.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.